BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carmen B, Angeles M, Ana M, María AJ. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004;99:811-28. [DOI: 10.1111/j.1360-0443.2004.00763.x] [Cited by in Crossref: 308] [Cited by in F6Publishing: 262] [Article Influence: 17.1] [Reference Citation Analysis]
Number Citing Articles
1 Garcia-romeu A, Davis AK, Erowid F, Erowid E, Griffiths RR, Johnson MW. Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 2019;33:1088-101. [DOI: 10.1177/0269881119845793] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
2 Yoon G, Kim SW, Thuras P, Westermeyer J. Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: an open-label study. Hum Psychopharmacol 2011;26:125-32. [PMID: 21437991 DOI: 10.1002/hup.1183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
3 Laaksonen E, Koski-jännes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol and Alcoholism 2008;43:53-61. [DOI: 10.1093/alcalc/agm136] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
4 Davies DL, Bortolato M, Finn DA, Ramaker MJ, Barak S, Ron D, Liang J, Olsen RW. Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcohol Clin Exp Res 2013;37:8-15. [PMID: 22671690 DOI: 10.1111/j.1530-0277.2012.01846.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
5 Jin C, Decker AM, Makhijani VH, Besheer J, Darcq E, Kieffer BL, Maitra R. Discovery of a Potent, Selective, and Brain-Penetrant Small Molecule that Activates the Orphan Receptor GPR88 and Reduces Alcohol Intake. J Med Chem 2018;61:6748-58. [PMID: 30011199 DOI: 10.1021/acs.jmedchem.8b00566] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
6 Lingford-hughes A, Welch S, Peters L, Nutt D; With expert reviewers (in alphabetical order): Ball D, Buntwal N, Chick J, Crome I, Daly C, Dar K, Day E, Duka T, Finch E, Law F, Marshall EJ, Munafo M, Myles J, Porter S, Raistrick D, Reed LJ, Reid A, Sell L, Sinclair J, Tyrer P, West R, Williams T, Winstock A. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012;26:899-952. [DOI: 10.1177/0269881112444324] [Cited by in Crossref: 174] [Cited by in F6Publishing: 116] [Article Influence: 17.4] [Reference Citation Analysis]
7 Rouvinen-Lagerström N, Lahti J, Alho H, Kovanen L, Aalto M, Partonen T, Silander K, Sinclair D, Räikkönen K, Eriksson JG, Palotie A, Koskinen S, Saarikoski ST. μ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumption. Alcohol Alcohol 2013;48:519-25. [PMID: 23729673 DOI: 10.1093/alcalc/agt050] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
8 Hansson AC, Gründer G, Hirth N, Noori HR, Spanagel R, Sommer WH. Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. Neuroscience & Biobehavioral Reviews 2019;106:141-64. [DOI: 10.1016/j.neubiorev.2018.09.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
9 Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, Gadde KM, Gupta AK, O'Neil P, Schumacher D, Smith D, Dunayevich E, Tollefson GD, Weber E, Cowley MA. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:30-9. [PMID: 18997675 DOI: 10.1038/oby.2008.461] [Cited by in Crossref: 199] [Cited by in F6Publishing: 183] [Article Influence: 14.2] [Reference Citation Analysis]
10 Singh AK, Jiang Y, Benlhabib E, Gupta S. Herbal mixtures consisting of puerarin and either polyenylphosphatidylcholine or curcumin provide comprehensive protection against alcohol-related disorders in P rats receiving free choice water and 15% ethanol in pure water. J Med Food. 2007;10:526-542. [PMID: 17887948 DOI: 10.1089/jmf.2006.228] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
11 Giannola LI, De Caro V, Giandalia G, Siragusa MG, Tripodo C, Florena AM, Campisi G. Release of naltrexone on buccal mucosa: Permeation studies, histological aspects and matrix system design. European Journal of Pharmaceutics and Biopharmaceutics 2007;67:425-33. [DOI: 10.1016/j.ejpb.2007.02.020] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
12 Franck J, Jayaram-lindström N. Pharmacotherapy for alcohol dependence: status of current treatments. Current Opinion in Neurobiology 2013;23:692-9. [DOI: 10.1016/j.conb.2013.05.005] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
13 Wright TM, Myrick H. Acamprosate: a new tool in the battle against alcohol dependence. Neuropsychiatr Dis Treat 2006;2:445-53. [PMID: 19412493 DOI: 10.2147/nedt.2006.2.4.445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zastrozhin MS, Skryabin VY, Miroshkin SS, Bryun EA, Sychev DA. Pharmacogenetics of alcohol addiction: current perspectives. Appl Clin Genet 2019;12:131-40. [PMID: 31372024 DOI: 10.2147/TACG.S206745] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
15 Job MO, Tang A, Hall FS, Sora I, Uhl GR, Bergeson SE, Gonzales RA. Mu (mu) opioid receptor regulation of ethanol-induced dopamine response in the ventral striatum: evidence of genotype specific sexual dimorphic epistasis. Biol Psychiatry 2007;62:627-34. [PMID: 17336938 DOI: 10.1016/j.biopsych.2006.11.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
16 Keller NE, Hennings AC, Dunsmoor JE. Behavioral and neural processes in counterconditioning: Past and future directions. Behav Res Ther 2020;125:103532. [PMID: 31881357 DOI: 10.1016/j.brat.2019.103532] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
17 Witkiewitz K, Alan Marlatt G. Overview of harm reduction treatments for alcohol problems. International Journal of Drug Policy 2006;17:285-94. [DOI: 10.1016/j.drugpo.2006.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
18 Hammond CJ. The Role of Pharmacotherapy in the Treatment of Adolescent Substance Use Disorders. Child Adolesc Psychiatr Clin N Am 2016;25:685-711. [PMID: 27613346 DOI: 10.1016/j.chc.2016.05.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
19 Berrettini W. Opioid pharmacogenetics of alcohol addiction. Cold Spring Harb Perspect Med 2013;3:a012203. [PMID: 23729643 DOI: 10.1101/cshperspect.a012203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
20 Cippitelli A, Karlsson C, Shaw JL, Thorsell A, Gehlert DR, Heilig M. Suppression of alcohol self-administration and reinstatement of alcohol seeking by melanin-concentrating hormone receptor 1 (MCH1-R) antagonism in Wistar rats. Psychopharmacology (Berl) 2010;211:367-75. [PMID: 20628734 DOI: 10.1007/s00213-010-1891-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
21 Ripley TL, Stephens DN. Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. Br J Pharmacol. 2011;164:1335-1356. [PMID: 21470204 DOI: 10.1111/j.1476-5381.2011.01406.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
22 Roozen HG, de Waart R, van den Brink W. Efficacy and Tolerability of Naltrexone in the Treatment of Alcohol Dependence: Oral versus Injectable Delivery. Eur Addict Res 2007;13:201-6. [DOI: 10.1159/000104882] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
23 Froehlich JC, Nicholson ER, Dilley JE, Filosa NJ, Rademacher LC, Smith TN. Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats. Alcohol Clin Exp Res 2017;41:1510-7. [PMID: 28617959 DOI: 10.1111/acer.13432] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
24 Dore G, Lo K, Juckes L, Bezyan S, Latt N. Clinical Experience with Baclofen in the Management of Alcohol-Dependent Patients with Psychiatric Comorbidity: A Selected Case Series. Alcohol and Alcoholism 2011;46:714-20. [DOI: 10.1093/alcalc/agr131] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
25 Wackernah RC, Minnick MJ, Clapp P. Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment. Subst Abuse Rehabil 2014;5:1-12. [PMID: 24648792 DOI: 10.2147/SAR.S37907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
26 Cannella N, Ubaldi M, Masi A, Bramucci M, Roberto M, Bifone A, Ciccocioppo R. Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. Neurosci Biobehav Rev 2019;103:384-98. [PMID: 31112713 DOI: 10.1016/j.neubiorev.2019.05.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
27 Mason BJ, Lehert P. Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy. J Addict Med 2009;3:164-71. [PMID: 21769013 DOI: 10.1097/ADM.0b013e3181917d53] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
28 Ray LA Ph.D, Bujarski S Ph.D, Grodin E Ph.D, Hartwell E Ph.D, Green R M.A, Venegas A B.S, Lim AC M.A, Gillis A M.D, Miotto K M.D. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse 2019;45:124-40. [PMID: 30373394 DOI: 10.1080/00952990.2018.1528265] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
29 [DOI: 10.1101/2021.02.03.21251107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Castro LA, Laranjeira R. Ensaio clínico duplo-cego randomizado e placebocontrolado com naltrexona e intervenção breve no tratamento ambulatorial da dependência de álcool. J bras psiquiatr 2009;58:79-85. [DOI: 10.1590/s0047-20852009000200002] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
31 Olmsted CL, Kockler DR. Topiramate for alcohol dependence. Ann Pharmacother 2008;42:1475-80. [PMID: 18698008 DOI: 10.1345/aph.1L157] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
32 Karlsson RM, Adermark L, Molander A, Perreau-Lenz S, Singley E, Solomon M, Holmes A, Tanaka K, Lovinger DM, Spanagel R, Heilig M. Reduced alcohol intake and reward associated with impaired endocannabinoid signaling in mice with a deletion of the glutamate transporter GLAST. Neuropharmacology 2012;63:181-9. [PMID: 22342743 DOI: 10.1016/j.neuropharm.2012.01.027] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
33 Edens E, Massa A, Petrakis I. Novel pharmacological approaches to drug abuse treatment. Curr Top Behav Neurosci 2010;3:343-86. [PMID: 21161760 DOI: 10.1007/7854_2009_29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
34 Warnault V, Darcq E, Levine A, Barak S, Ron D. Chromatin remodeling--a novel strategy to control excessive alcohol drinking. Transl Psychiatry 2013;3:e231. [PMID: 23423140 DOI: 10.1038/tp.2013.4] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 11.4] [Reference Citation Analysis]
35 Faccidomo S, Swaim KS, Saunders BL, Santanam TS, Taylor SM, Kim M, Reid GT, Eastman VR, Hodge CW. Mining the nucleus accumbens proteome for novel targets of alcohol self-administration in male C57BL/6J mice. Psychopharmacology (Berl) 2018;235:1681-96. [PMID: 29502276 DOI: 10.1007/s00213-018-4870-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Breese GR, Sinha R, Heilig M. Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. Pharmacol Ther 2011;129:149-71. [PMID: 20951730 DOI: 10.1016/j.pharmthera.2010.09.007] [Cited by in Crossref: 147] [Cited by in F6Publishing: 139] [Article Influence: 12.3] [Reference Citation Analysis]
37 Taylor E, Timko C, Harris AHS, Yu M, Finlay AK. Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration. Addict Sci Clin Pract 2019;14:1. [PMID: 30602392 DOI: 10.1186/s13722-018-0129-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008;103:2035-2044. [PMID: 18855810 DOI: 10.1111/j.1360-0443.2008.02355.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 6.4] [Reference Citation Analysis]
39 Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE, MacKillop J, Swift RM, Abrams DB, Shiffman S, Paty JA. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 2008;32:58-66. [PMID: 18028530 DOI: 10.1111/j.1530-0277.2007.00545.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 5.8] [Reference Citation Analysis]
40 Hwa LS, Kalinichev M, Haddouk H, Poli S, Miczek KA. Reduction of excessive alcohol drinking by a novel GABAB receptor positive allosteric modulator ADX71441 in mice. Psychopharmacology (Berl) 2014;231:333-43. [PMID: 23975038 DOI: 10.1007/s00213-013-3245-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
41 Litten RZ, Fertig J, Mattson M, Egli M. Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opinion on Emerging Drugs 2005;10:323-43. [DOI: 10.1517/14728214.10.2.323] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
42 Navarro HJ, Shakeshaft A, Doran CM, Petrie DJ. The cost-effectiveness of tailored, postal feedback on general practitioners’ prescribing of pharmacotherapies for alcohol dependence. Drug and Alcohol Dependence 2012;124:207-15. [DOI: 10.1016/j.drugalcdep.2012.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
43 Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf 2010;9:177-88. [PMID: 20021295 DOI: 10.1517/14740330903512943] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
44 Cottencin O, Guardia D, Karila L, Rolland B. Alcoologie clinique. La Presse Médicale 2012;41:1248-58. [DOI: 10.1016/j.lpm.2012.07.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
45 Kang SY, Kwon OS, Moon JY, Cho SJ, Choi KH, Kim J, Ahn SH, Ryu Y. Mechanical Stimulation of the HT7 Acupuncture Point to Reduce Ethanol Self-Administration in Rats. Evid Based Complement Alternat Med 2017;2017:6578621. [PMID: 28638432 DOI: 10.1155/2017/6578621] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
46 Mason BJ, Lehert P. The Effects of Current Subsyndromal Psychiatric Symptoms or Past Psychopathology on Alcohol Dependence Treatment Outcomes and Acamprosate Efficacy. The American Journal on Addictions 2010;19:147-54. [DOI: 10.1111/j.1521-0391.2009.00013.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
47 Barak S, Ahmadiantehrani S, Logrip ML, Ron D. GDNF and alcohol use disorder. Addict Biol 2019;24:335-43. [PMID: 29726054 DOI: 10.1111/adb.12628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
48 Yahn SL, Watterson LR, Olive MF. Safety and efficacy of acamprosate for the treatment of alcohol dependence. Subst Abuse 2013;6:1-12. [PMID: 23399877 DOI: 10.4137/SART.S9345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.1] [Reference Citation Analysis]
49 Guerra JVS, Dias MMG, Brilhante AJVC, Terra MF, García-Arévalo M, Figueira ACM. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients 2021;13:2830. [PMID: 34444990 DOI: 10.3390/nu13082830] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res 2011;35:1804-11. [PMID: 21575016 DOI: 10.1111/j.1530-0277.2011.01524.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
51 Ray LA, Bujarski S, Roche DJ. Subjective Response to Alcohol as a Research Domain Criterion. Alcohol Clin Exp Res 2016;40:6-17. [PMID: 26727518 DOI: 10.1111/acer.12927] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
52 Almatroudi A, Husbands SM, Bailey CP, Bailey SJ. Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. J Psychopharmacol 2015;29:812-21. [PMID: 26045511 DOI: 10.1177/0269881115586937] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
53 Pagano ME, Delos-Reyes CM, Wasilow S, Svala KM, Kurtz SP. Smoking Cessation and Adolescent Treatment Response With Comorbid ADHD. J Subst Abuse Treat 2016;70:21-7. [PMID: 27692184 DOI: 10.1016/j.jsat.2016.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008;65:135-44. [PMID: 18250251 DOI: 10.1001/archpsyc.65.2.135] [Cited by in Crossref: 306] [Cited by in F6Publishing: 266] [Article Influence: 21.9] [Reference Citation Analysis]
55 Chamorro AJ, Marcos M, Mirón-Canelo JA, Pastor I, González-Sarmiento R, Laso FJ. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol 2012;17:505-12. [PMID: 22515274 DOI: 10.1111/j.1369-1600.2012.00442.x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 10.4] [Reference Citation Analysis]
56 Abraham AJ, Rieckmann T, McNulty T, Kovas AE, Roman PM. Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addict Behav 2011;36:576-83. [PMID: 21382667 DOI: 10.1016/j.addbeh.2011.01.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
57 Berrettini W. Alcohol addiction and the mu-opioid receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016;65:228-33. [DOI: 10.1016/j.pnpbp.2015.07.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
58 Scott LJ, Figgitt DP, Keam SJ, Waugh J. Acamprosate: A Review of its Use in the Maintenance of Abstinence in Patients with Alcohol Dependence. CNS Drugs 2005;19:445-64. [DOI: 10.2165/00023210-200519050-00006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
59 Ghirmai S, Azar MR, Polgar WE, Berzetei-Gurske I, Cashman JR. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents. J Med Chem 2008;51:1913-24. [PMID: 18298057 DOI: 10.1021/jm701060e] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
60 Xu BJ, Zheng YN, Sung CK. Natural medicines for alcoholism treatment: a review. Drug Alcohol Rev 2005;24:525-36. [PMID: 16361209 DOI: 10.1080/09595230500293795] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
61 Liu J, Shi YC, Lee DY. Applications of Pueraria lobata in treating diabetics and reducing alcohol drinking. Chin Herb Med 2019;11:141-9. [PMID: 32831815 DOI: 10.1016/j.chmed.2019.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
62 Kranzler HR, Edenberg HJ. Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des 2010;16:2141-8. [PMID: 20482509 DOI: 10.2174/138161210791516387] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
63 Bilbao A, Robinson JE, Heilig M, Malanga C, Spanagel R, Sommer WH, Thorsell A. A Pharmacogenetic Determinant of Mu-Opioid Receptor Antagonist Effects on Alcohol Reward and Consumption: Evidence from Humanized Mice. Biological Psychiatry 2015;77:850-8. [DOI: 10.1016/j.biopsych.2014.08.021] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
64 Olney JJ, Navarro M, Thiele TE. Targeting central melanocortin receptors: a promising novel approach for treating alcohol abuse disorders. Front Neurosci 2014;8:128. [PMID: 24917782 DOI: 10.3389/fnins.2014.00128] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
65 Kaczkurkin AN, Asnaani A, Alpert E, Foa EB. The impact of treatment condition and the lagged effects of PTSD symptom severity and alcohol use on changes in alcohol craving. Behav Res Ther 2016;79:7-14. [PMID: 26905901 DOI: 10.1016/j.brat.2016.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
66 Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ. Treatment of alcoholic liver disease. Therap Adv Gastroenterol. 2011;4:63-81. [PMID: 21317995 DOI: 10.1177/1756283x10378925] [Cited by in Crossref: 84] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
67 Walter M, Gerhard U, Duersteler-MacFarland KM, Weijers HG, Boening J, Wiesbeck GA. Social factors but not stress-coping styles predict relapse in detoxified alcoholics. Neuropsychobiology 2006;54:100-6. [PMID: 17108710 DOI: 10.1159/000096991] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
68 Saitz R. Treatment of alcohol and other drug dependence. Liver Transpl. 2007;13:S59-S64. [PMID: 17969089 DOI: 10.1002/lt.21339] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
69 Santiesteban-Lores LE, Carneiro MC, Isaac L, Bavia L. Complement System in Alcohol-Associated Liver Disease. Immunol Lett 2021;236:37-50. [PMID: 34111475 DOI: 10.1016/j.imlet.2021.05.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Gupta M, Verma P, Rastogi R, Arora S, Elwadhi D. Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. The American Journal of Drug and Alcohol Abuse 2017;43:324-31. [DOI: 10.1080/00952990.2016.1240797] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
71 Kranzler HR, McKay JR. Personalized treatment of alcohol dependence. Curr Psychiatry Rep 2012;14:486-93. [PMID: 22810115 DOI: 10.1007/s11920-012-0296-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
72 Robertson AG, Swartz MS. Extended-release naltrexone and drug treatment courts: Policy and evidence for implementing an evidence-based treatment. Journal of Substance Abuse Treatment 2018;85:101-4. [DOI: 10.1016/j.jsat.2017.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
73 Feeney GF, Connor JP, McD Young R, Tucker J, McPherson A. Is acamprosate use in alcohol dependence treatment reflected in improved subjective health status outcomes beyond cognitive behavioural therapy alone?. J Addict Dis 2006;25:49-58. [PMID: 17088225 DOI: 10.1300/J069v25n04_05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Park J, Kim S, Hwang I, Bae K, Bae J, Song D. Green Tea Extract Co-administered with a Polymer Effectively Prevents Alcoholic Liver Damage by Prolonged Inhibition of Alcohol Absorption in Mice. Alcohol and Alcoholism 2013;48:59-67. [DOI: 10.1093/alcalc/ags118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
75 Grover S, Basu D, Bhateja G. Pharmacoprophylaxis of alcohol dependence: Review and update Part II: Efficacy. Indian J Psychiatry 2007;49:26-33. [PMID: 20640062 DOI: 10.4103/0019-5545.31515] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
76 Oberlin BG, Bristow RE, Heighton ME, Grahame NJ. Pharmacologic dissociation between impulsivity and alcohol drinking in high alcohol preferring mice. Alcohol Clin Exp Res 2010;34:1363-75. [PMID: 20491739 DOI: 10.1111/j.1530-0277.2010.01220.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 0.4] [Reference Citation Analysis]
77 Johnson C, Dong H, Ahamad K, Hayashi K, Milloy MJ, Kerr T, Wood E. Impact of binge alcohol on mortality among people who inject drugs. Addict Behav Rep 2015;2:28-32. [PMID: 26097893 DOI: 10.1016/j.abrep.2015.05.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
78 García MLG, Blasco-Algora S, Fernández-Rodríguez CM. Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence. World J Gastroenterol 2015; 21(28): 8516-8526 [PMID: 26229395 DOI: 10.3748/wjg.v21.i28.8516] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
79 Paz RD, Tardito S, Atzori M, Tseng KY. Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 2008;18:773-86. [PMID: 18650071 DOI: 10.1016/j.euroneuro.2008.06.005] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 6.1] [Reference Citation Analysis]
80 Tambour S, Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol 2007;21. [DOI: 10.1111/j.1472-8206.2006.00459.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
81 Grodin EN, Bujarski S, Venegas A, Baskerville WA, Nieto SJ, Jentsch JD, Ray LA. Reward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool. Alcohol Alcohol 2019;54:574-83. [PMID: 31557278 DOI: 10.1093/alcalc/agz075] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
82 Jarosz J, Miernik K, Wąchal M, Walczak J, Krumpl G. Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: a meta-analysis of randomized controlled trials. Am J Drug Alcohol Abuse 2013;39:144-60. [PMID: 23721530 DOI: 10.3109/00952990.2013.796961] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
83 Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, Möller H, The Wfsbp Task Force On Treatment G, Soyka M, Kranzler HR, Berglund M, Gorelick D, Hesselbrock V, Johnson BA, Möller H, The Wfsbp Task Force On Treatment G. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. The World Journal of Biological Psychiatry 2009;9:6-23. [DOI: 10.1080/15622970801896390] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
84 Cashman JR, Azar MR. Potent inhibition of alcohol self-administration in alcohol-preferring rats by a κ-opioid receptor antagonist. J Pharmacol Exp Ther 2014;350:171-80. [PMID: 24817033 DOI: 10.1124/jpet.114.214262] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
85 Heilig M, Thorsell A, Sommer WH, Hansson AC, Ramchandani VA, George DT, Hommer D, Barr CS. Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev 2010;35:334-44. [PMID: 19941895 DOI: 10.1016/j.neubiorev.2009.11.018] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 5.9] [Reference Citation Analysis]
86 Hagedorn HJ, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Wisdom JP, Harris AH. Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. Implement Sci 2016;11:64. [PMID: 27164835 DOI: 10.1186/s13012-016-0431-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
87 Helton SG, Lohoff FW. Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. Psychiatry Res 2015;230:121-9. [PMID: 26455758 DOI: 10.1016/j.psychres.2015.09.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
88 Jørgensen CH, Pedersen B, Tønnesen H. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res. 2011;35:1749-1758. [PMID: 21615426 DOI: 10.1111/j.1530-0277.2011.01523.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 74] [Article Influence: 8.3] [Reference Citation Analysis]
89 Kopak AM. Breaking the addictive cycle of the system: improving US criminal justice practices to address substance use disorders. Int J Prison Health 2015;11:4-16. [PMID: 25751703 DOI: 10.1108/IJPH-07-2014-0023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
90 Rösner S, Hackl-herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M; Cochrane Drugs and Alcohol Group. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd001867.pub3] [Cited by in Crossref: 73] [Article Influence: 6.1] [Reference Citation Analysis]
91 Lucey MR, Silverman BL, Illeperuma A, O'Brien CP. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res 2008;32:498-504. [PMID: 18241321 DOI: 10.1111/j.1530-0277.2007.00593.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
92 Setiawan E, Pihl RO, Cox SML, Gianoulakis C, Palmour RM, Benkelfat C, Leyton M. The Effect of Naltrexone on Alcohol’s Stimulant Properties and Self-Administration Behavior in Social Drinkers: Influence of Gender and Genotype: GROUP DIFFERENCES IN NALTREXONE’S EFFECTS. Alcoholism: Clinical and Experimental Research 2011;35:1134-41. [DOI: 10.1111/j.1530-0277.2011.01446.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
93 Verholleman A, Victorri-Vigneau C, Laforgue E, Derkinderen P, Verstuyft C, Grall-Bronnec M. Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of OPRM1 A/G Polymorphism on Its Effectiveness. Int J Mol Sci 2020;21:E3002. [PMID: 32344532 DOI: 10.3390/ijms21083002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
94 Moore RA, Aubin HJ. Do placebo response rates from cessation trials inform on strength of addictions? Int J Environ Res Public Health 2012;9:192-211. [PMID: 22470287 DOI: 10.3390/ijerph9010192] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
95 Garbutt JC, Osborne M, Gallop R, Barkenbus J, Grace K, Cody M, Flannery B, Kampov-Polevoy AB. Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. Alcohol Alcohol 2009;44:293-300. [PMID: 19189996 DOI: 10.1093/alcalc/agn122] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
96 Cho SH, Whang WW. Acupuncture for alcohol dependence: a systematic review. Alcohol Clin Exp Res 2009;33:1305-13. [PMID: 19413653 DOI: 10.1111/j.1530-0277.2009.00959.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
97 Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, Ten Have T, Wortman S, Dundon W, Dackis C, Volpicelli JR, O'Brien CP. A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention. Alcohol Clin Exp Res 2008;32:1299-308. [PMID: 18540910 DOI: 10.1111/j.1530-0277.2008.00698.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
98 Marienfeld C, Iheanacho T, Issa M, Rosenheck RA. Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study. Addict Behav 2014;39:434-8. [PMID: 23790742 DOI: 10.1016/j.addbeh.2013.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
99 Assanangkornchai S, Srisurapanont M. The treatment of alcohol dependence: . Current Opinion in Psychiatry 2007;20:222-7. [DOI: 10.1097/yco.0b013e3280fa837d] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
100 Thompson A, Owens L, Pushpakom SP, Faizal M, Pirmohamed M. Pharmacotherapy for alcohol dependence: A stratified approach. Pharmacol Ther 2015;153:10-24. [PMID: 25985735 DOI: 10.1016/j.pharmthera.2015.05.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
101 Bath KG, Russo SJ, Pleil KE, Wohleb ES, Duman RS, Radley JJ. Circuit and synaptic mechanisms of repeated stress: Perspectives from differing contexts, duration, and development. Neurobiol Stress 2017;7:137-51. [PMID: 29276735 DOI: 10.1016/j.ynstr.2017.05.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
102 Mellentin AI, Skøt L, Nielsen B, Schippers GM, Nielsen AS, Stenager E, Juhl C. Cue exposure therapy for the treatment of alcohol use disorders: A meta-analytic review. Clinical Psychology Review 2017;57:195-207. [DOI: 10.1016/j.cpr.2017.07.006] [Cited by in Crossref: 59] [Cited by in F6Publishing: 41] [Article Influence: 11.8] [Reference Citation Analysis]
103 Barr CS, Chen SA, Schwandt ML, Lindell SG, Sun H, Suomi SJ, Heilig M. Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry 2010;67:78-80. [PMID: 19748082 DOI: 10.1016/j.biopsych.2009.07.026] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
104 Pettinati HM, Gastfriend DR, Dong Q, Kranzler HR, O’Malley SS. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res. 2009;33:350-356. [PMID: 19053979 DOI: 10.1111/j.1530-0277.2008.00843.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
105 Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006;26:290-302. [PMID: 16702894 DOI: 10.1097/01.jcp.0000222512.25649.08] [Cited by in Crossref: 236] [Cited by in F6Publishing: 177] [Article Influence: 14.8] [Reference Citation Analysis]
106 Lohoff FW. Pharmacotherapies and personalized medicine for alcohol use disorder: a review. Pharmacogenomics 2020;21:1117-38. [PMID: 32807012 DOI: 10.2217/pgs-2020-0079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Baros AM, Latham PK, Anton RF. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res 2008;32:771-6. [PMID: 18336635 DOI: 10.1111/j.1530-0277.2008.00633.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
108 Johnson BA, Koob GF, Schuckit MA, Mason BJ, Ait-Daoud N. Understanding and treating alcohol dependence. Alcohol Clin Exp Res 2006;30:567-84. [PMID: 16499499 DOI: 10.1111/j.1530-0277.2005.00066.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
109 Campanella S, Petit G, Verbanck P, Kornreich C, Noel X. How cognitive assessment through clinical neurophysiology may help optimize chronic alcoholism treatment. Neurophysiologie Clinique/Clinical Neurophysiology 2011;41:115-23. [DOI: 10.1016/j.neucli.2011.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
110 Popova S, Mohapatra S, Patra J, Duhig A, Rehm J. A literature review of cost-benefit analyses for the treatment of alcohol dependence. Int J Environ Res Public Health 2011;8:3351-64. [PMID: 21909311 DOI: 10.3390/ijerph8083351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
111 Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, Morton K, Palmer J, Bonaventure P, Carruthers NI, Lovenberg TW, Boggs J, Galici R. Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology 2011;215:191-203. [DOI: 10.1007/s00213-010-2127-x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 8.3] [Reference Citation Analysis]
112 Bence C, Cottencin O, Deheul S, Gautier S, Bordet R, Rolland B. Baclofen-induced edema in alcohol use disorders. J Clin Pharmacol 2014;54:478-81. [PMID: 24293402 DOI: 10.1002/jcph.233] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
113 Koeter MW, van den Brink W, Lehert P. Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence. J Subst Abuse Treat 2010;39:218-26. [PMID: 20627222 DOI: 10.1016/j.jsat.2010.06.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
114 Crome IB. Overview: Beyond guidelines and guidance—psychosocial perspectives on treatment interventions for young people with substance problems in the United Kingdom. Drugs: Education, Prevention and Policy 2009;13:203-24. [DOI: 10.1080/09687630600607316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
115 Bharadwaj B, Selvakumar N, Kuppili PP. Pharmacotherapy for relapse prevention of alcohol use disorder in the Indian setting: A systematic review. Ind Psychiatry J 2018;27:163-71. [PMID: 31359967 DOI: 10.4103/ipj.ipj_79_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Mitchell JM, Bergren LJ, Chen KS, Rowbotham MC, Fields HL. Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol. Neurobiology of Disease 2009;33:72-80. [DOI: 10.1016/j.nbd.2008.09.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
117 Clapp P. Current progress in pharmacologic treatment strategies for alcohol dependence. Expert Rev Clin Pharmacol 2012;5:427-35. [PMID: 22943122 DOI: 10.1586/ecp.12.31] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
118 Lukas SE, Lowen SB, Lindsey KP, Conn N, Tartarini W, Rodolico J, Mallya G, Palmer C, Penetar DM. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study. Neuroimage 2013;78:176-85. [PMID: 23571420 DOI: 10.1016/j.neuroimage.2013.03.055] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 5.8] [Reference Citation Analysis]
119 Metz VE, Brandt L, Unger A, Fischer G. Substance abuse/dependence treatment: a European perspective. Subst Abus 2014;35:309-20. [PMID: 24766667 DOI: 10.1080/08897077.2014.909377] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
120 Heidbreder C. Novel pharmacotherapeutic targets for the management of drug addiction. Eur J Pharmacol 2005;526:101-12. [PMID: 16253234 DOI: 10.1016/j.ejphar.2005.09.038] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
121 Khoja S, Huynh N, Warnecke AMP, Asatryan L, Jakowec MW, Davies DL. Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. Psychopharmacology (Berl) 2018;235:1697-709. [PMID: 29500584 DOI: 10.1007/s00213-018-4869-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
122 Sommer W, Hyytiä P, Kiianmaa K. The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking. Addict Biol 2006;11:289-309. [PMID: 16961760 DOI: 10.1111/j.1369-1600.2006.00037.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 6.8] [Reference Citation Analysis]
123 Kim MS, Ong M, Qu X. Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? World J Gastroenterol 2016; 22(1): 8-23 [PMID: 26755857 DOI: 10.3748/wjg.v22.i1.8] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
124 Ginsburg BC, Lamb RJ. Drug effects on multiple and concurrent schedules of ethanol- and food-maintained behaviour: context-dependent selectivity. Br J Pharmacol 2014;171:3499-510. [PMID: 24697498 DOI: 10.1111/bph.12707] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
125 Walters D, Connor JP, Feeney GFX, Young RM. The Cost Effectiveness of Naltrexone Added to Cognitive-Behavioral Therapy in the Treatment of Alcohol Dependence. Journal of Addictive Diseases 2009;28:137-44. [DOI: 10.1080/10550880902772456] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
126 Sawares AS, Shen N, Xue Y, Abi-Jaoude A, Wiljer D. The Impact of Mobile Apps on Alcohol Use Disorder: A Systematic Review Protocol. JMIR Res Protoc 2017;6:e49. [PMID: 28377366 DOI: 10.2196/resprot.6975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
127 Gastfriend DR. Intramuscular extended-release naltrexone: current evidence. Ann N Y Acad Sci 2011;1216:144-66. [PMID: 21272018 DOI: 10.1111/j.1749-6632.2010.05900.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
128 Fitzgerald JP, McCarty D. Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach. Psychol Serv 2009;6:74-84. [PMID: 20401336 DOI: 10.1037/a0013420] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
129 de Moura FB, Kohut SJ, Bergman J. Medications development for food-based and drug use disorders. Adv Pharmacol 2019;86:197-236. [PMID: 31378252 DOI: 10.1016/bs.apha.2019.04.005] [Reference Citation Analysis]
130 . Medications to treat heavy drinking: are we there yet? Addiction 2006;101:153-4. [DOI: 10.1111/j.1360-0443.2006.01324.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
131 Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res 2007;31:775-82. [PMID: 17378918 DOI: 10.1111/j.1530-0277.2007.00360.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 5.1] [Reference Citation Analysis]
132 Kelly JF, Yeterian JD. Mutual-Help Groups for Dually Diagnosed Individuals: Rationale, Description, and Review of the Evidence. Journal of Groups in Addiction & Recovery 2008;3:217-42. [DOI: 10.1080/15560350802424852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
133 Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O'malley SS, Krystal JH. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry 2007;61:1290-5. [PMID: 17224132 DOI: 10.1016/j.biopsych.2006.09.038] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
134 Ryan PJ, Kastman HE, Krstew EV, Rosengren KJ, Hossain MA, Churilov L, Wade JD, Gundlach AL, Lawrence AJ. Relaxin-3/RXFP3 system regulates alcohol-seeking. Proc Natl Acad Sci U S A 2013;110:20789-94. [PMID: 24297931 DOI: 10.1073/pnas.1317807110] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
135 Ho D, Towns B, Grodin EN, Ray LA. A novel human laboratory model for screening medications for alcohol use disorder. Trials 2020;21:947. [PMID: 33225963 DOI: 10.1186/s13063-020-04842-w] [Reference Citation Analysis]
136 Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 2012;223:299-306. [PMID: 22547331 DOI: 10.1007/s00213-012-2717-x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 112] [Article Influence: 12.3] [Reference Citation Analysis]
137 Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol. 2008;75:34-56. [PMID: 17880925 DOI: 10.1016/j.bcp.2007.08.005] [Cited by in Crossref: 165] [Cited by in F6Publishing: 149] [Article Influence: 11.0] [Reference Citation Analysis]
138 Al-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK. Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. Pharmgenomics Pers Med 2012;5:99-111. [PMID: 23226066 DOI: 10.2147/PGPM.S33351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
139 Westphal JR, Jackson AC, Thomas SA, Blaszczynski A. A Review of Pharmacological Approaches to Intervention in Pathological Gambling. Journal of Social Work Practice in the Addictions 2008;8:192-207. [DOI: 10.1080/15332560802156968] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
140 Czachowski CL, Delory MJ. Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. Psychopharmacology (Berl) 2009;204:335-48. [PMID: 19153715 DOI: 10.1007/s00213-009-1465-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
141 Garbutt JC. Alcoholism. In: Fatemi SH, Clayton PJ, editors. The Medical Basis of Psychiatry. Totowa: Humana Press; 2008. pp. 227-49. [DOI: 10.1007/978-1-59745-252-6_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Swift R, Leggio L. Adjunctive Pharmacotherapy in the Treatment of Alcohol and Drug Dependence. Evidence-Based Addiction Treatment. Elsevier; 2009. pp. 287-310. [DOI: 10.1016/b978-0-12-374348-0.00015-x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
143 Knudsen HK, Roman PM. The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study. J Subst Abuse Treat 2016;62:62-7. [PMID: 26689318 DOI: 10.1016/j.jsat.2015.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Rolland B, Deheul S, Danel T, Bordet R, Cottencin O. [A system of prescriptions without drug approval: example of baclofen]. Therapie 2010;65:511-8. [PMID: 21176757 DOI: 10.2515/therapie/2010073] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
145 Glass JE, Bobb JF, Lee AK, Richards JE, Lapham GT, Ludman E, Achtmeyer C, Caldeiro RM, Parrish R, Williams EC, Lozano P, Bradley KA. Study protocol: a cluster-randomized trial implementing Sustained Patient-centered Alcohol-related Care (SPARC trial). Implement Sci 2018;13:108. [PMID: 30081930 DOI: 10.1186/s13012-018-0795-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
146 Mason BJ, Crean R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother 2007;7:1465-77. [PMID: 17997696 DOI: 10.1586/14737175.7.11.1465] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
147 Biernacka JM, Coombes BJ, Batzler A, Ho AM, Geske JR, Frank J, Hodgkinson C, Skime M, Colby C, Zillich L, Pozsonyiova S, Ho MF, Kiefer F, Rietschel M, Weinshilboum R, O'Malley SS, Mann K, Anton R, Goldman D, Karpyak VM. Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology 2021. [PMID: 34302059 DOI: 10.1038/s41386-021-01097-0] [Reference Citation Analysis]
148 . Abstracts of the European Association of Poisons Centres and Clinical Toxicologists XXV International Congress. Clinical Toxicology 2008;43:387-538. [DOI: 10.1080/07313820500207624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Campisi G, Giannola LI, Florena AM, De Caro V, Schumacher A, Göttsche T, Paderni C, Wolff A. Bioavailability in vivo of naltrexone following transbuccal administration by an electronically-controlled intraoral device: A trial on pigs. Journal of Controlled Release 2010;145:214-20. [DOI: 10.1016/j.jconrel.2010.04.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
150 Roozen HG, de Waart R, van der Windt DA, van den Brink W, de Jong CA, Kerkhof AJ. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. Eur Neuropsychopharmacol. 2006;16:311-323. [PMID: 16361086 DOI: 10.1016/j.euroneuro.2005.11.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
151 Feinn R, Kranzler HR. Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies? Alcohol Clin Exp Res 2005;29:983-8. [PMID: 15976524 DOI: 10.1097/01.alc.0000171061.03686.bc] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
152 Cohen SM, Alexander RS, Holt SR. The Spectrum of Alcohol Use: Epidemiology, Diagnosis, and Treatment. Med Clin North Am 2022;106:43-60. [PMID: 34823734 DOI: 10.1016/j.mcna.2021.08.003] [Reference Citation Analysis]
153 Jakubowiak WM, Bogorodskaya EM, Borisov SE, Danilova ID, Lomakina OB, Kourbatova EV. Impact of socio-psychological factors on treatment adherence of TB patients in Russia. Tuberculosis (Edinb) 2008;88:495-502. [PMID: 18501675 DOI: 10.1016/j.tube.2008.03.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
154 Evans SM, Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcohol Clin Exp Res 2009;33:19-30. [PMID: 18840257 DOI: 10.1111/j.1530-0277.2008.00805.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
155 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of alcoholic liver disease. Clin Mol Hepatol. 2013;19:216-254. [PMID: 24133661 DOI: 10.3350/cmh.2013.19.3.216] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
156 O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007;27:507-12. [PMID: 17873686 DOI: 10.1097/jcp.0b013e31814ce50d] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 5.2] [Reference Citation Analysis]
157 Heilig M, Goldman D, Berrettini W, O'Brien CP. Pharmacogenetic approaches to the treatment of alcohol addiction. Nat Rev Neurosci 2011;12:670-84. [PMID: 22011682 DOI: 10.1038/nrn3110] [Cited by in Crossref: 163] [Cited by in F6Publishing: 153] [Article Influence: 14.8] [Reference Citation Analysis]
158 Heijdra Suasnabar JM, Hipple Walters B. Community-based psychosocial substance use disorder interventions in low-and-middle-income countries: a narrative literature review. Int J Ment Health Syst 2020;14:74. [PMID: 33062049 DOI: 10.1186/s13033-020-00405-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 Rolland B, Paille F, Gillet C, Rigaud A, Moirand R, Dano C, Dematteis M, Mann K, Aubin HJ. Pharmacotherapy for Alcohol Dependence: The 2015 Recommendations of the French Alcohol Society, Issued in Partnership with the European Federation of Addiction Societies. CNS Neurosci Ther 2016;22:25-37. [PMID: 26768685 DOI: 10.1111/cns.12489] [Cited by in Crossref: 71] [Cited by in F6Publishing: 53] [Article Influence: 11.8] [Reference Citation Analysis]
160 Maruotti A, Rocci R. A mixed non-homogeneous hidden Markov model for categorical data, with application to alcohol consumption. Statist Med 2012;31:871-86. [DOI: 10.1002/sim.4478] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
161 van den Wildenberg E, Wiers RW, Dessers J, Janssen RG, Lambrichs EH, Smeets HJ, van Breukelen GJ. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 2007;31:1-10. [PMID: 17207095 DOI: 10.1111/j.1530-0277.2006.00258.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 97] [Article Influence: 7.7] [Reference Citation Analysis]
162 Ray LA, Krull JL, Leggio L. The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. Front Psychiatry 2010;1:26. [PMID: 21423437 DOI: 10.3389/fpsyt.2010.00026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
163 Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 2011;16:809-17. [PMID: 20479755 DOI: 10.1038/mp.2010.56] [Cited by in Crossref: 214] [Cited by in F6Publishing: 209] [Article Influence: 17.8] [Reference Citation Analysis]
164 Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med 2007;1:115-25. [PMID: 21768946 DOI: 10.1097/ADM.0b013e318156c26f] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
165 Kranzler HR, Tennen H, Armeli S, Chan G, Covault J, Arias A, Oncken C. Targeted naltrexone for problem drinkers. J Clin Psychopharmacol 2009;29:350-7. [PMID: 19593174 DOI: 10.1097/JCP.0b013e3181ac5213] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
166 Hood LE, Leyrer-Jackson JM, Olive MF. Pharmacotherapeutic management of co-morbid alcohol and opioid use. Expert Opin Pharmacother 2020;21:823-39. [PMID: 32103695 DOI: 10.1080/14656566.2020.1732349] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
167 Zalewska-kaszubska J, Górska D, Dyr W, Czarnecka E. Effect of chronic acamprosate treatment on voluntary alcohol intake and β-endorphin plasma levels in rats selectively bred for high alcohol preference. Neuroscience Letters 2008;431:221-5. [DOI: 10.1016/j.neulet.2007.11.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
168 Greenfield SF, Shields A, Connery HS, Livchits V, Yanov SA, Lastimoso CS, Strelis AK, Mishustin SP, Fitzmaurice G, Mathew TA, Shin S. Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation. Alcohol Clin Exp Res 2010;34:317-30. [PMID: 19930235 DOI: 10.1111/j.1530-0277.2009.01094.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
169 Fachin-scheit DJ, Frozino Ribeiro A, Pigatto G, Oliveira Goeldner F, Boerngen de Lacerda R. Development of a mouse model of ethanol addiction: naltrexone efficacy in reducing consumption but not craving. J Neural Transm 2006;113:1305-21. [DOI: 10.1007/s00702-005-0416-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
170 Cheng HY, Elbers RG, Higgins JP, Taylor A, MacArthur GJ, McGuinness L, Dawson S, López-López JA, Cowlishaw S, Hickman M, Kessler D. Therapeutic interventions for alcohol dependence in non-inpatient settings: a systematic review and network meta-analysis (protocol). Syst Rev 2017;6:77. [PMID: 28399899 DOI: 10.1186/s13643-017-0462-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
171 Rösner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008;22:11-23. [DOI: 10.1177/0269881107078308] [Cited by in Crossref: 96] [Cited by in F6Publishing: 73] [Article Influence: 6.4] [Reference Citation Analysis]
172 Woo GA, O'Brien C. Long-term management of alcoholic liver disease. Clin Liver Dis 2012;16:763-81. [PMID: 23101981 DOI: 10.1016/j.cld.2012.08.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
173 Witkiewitz K, Saville K, Hamreus K. Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility. Ther Clin Risk Manag 2012;8:45-53. [PMID: 22346357 DOI: 10.2147/TCRM.S23184] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
174 Soyka M, Roesner S. New pharmacological approaches for the treatment of alcoholism. Expert Opinion on Pharmacotherapy 2006;7:2341-53. [DOI: 10.1517/14656566.7.17.2341] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
175 Benegal V, Chand PK, Obot IS. Packages of care for alcohol use disorders in low- and middle-income countries. PLoS Med 2009;6:e1000170. [PMID: 19859536 DOI: 10.1371/journal.pmed.1000170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
176 Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006;101:1451-62. [DOI: 10.1111/j.1360-0443.2006.01555.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 6.3] [Reference Citation Analysis]
177 Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. Am J Addict 2008;17:463-8. [PMID: 19034737 DOI: 10.1080/10550490802409074] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
178 Rittenberg A, Hines AL, Alvanzo AAH, Chander G. Correlates of alcohol use disorder pharmacotherapy receipt in medically insured patients. Drug Alcohol Depend 2020;214:108174. [PMID: 32721788 DOI: 10.1016/j.drugalcdep.2020.108174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
179 Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS 2005;19 Suppl 3:S227-37. [PMID: 16251823 DOI: 10.1097/01.aids.0000192094.84624.c2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 2.7] [Reference Citation Analysis]
180 King A, Cao D, Vanier C, Wilcox T. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcohol Clin Exp Res 2009;33:1044-50. [PMID: 19302083 DOI: 10.1111/j.1530-0277.2009.00925.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
181 Bobb JF, Lee AK, Lapham GT, Oliver M, Ludman E, Achtmeyer C, Parrish R, Caldeiro RM, Lozano P, Richards JE, Bradley KA. Evaluation of a Pilot Implementation to Integrate Alcohol-Related Care within Primary Care. Int J Environ Res Public Health 2017;14:E1030. [PMID: 28885557 DOI: 10.3390/ijerph14091030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
182 Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. Br J Clin Pharmacol 2014;77:315-23. [PMID: 23278595 DOI: 10.1111/bcp.12070] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
183 Morris LS, Baek K, Tait R, Elliott R, Ersche KD, Flechais R, McGonigle J, Murphy A, Nestor LJ, Orban C, Passetti F, Paterson LM, Rabiner I, Reed L, Smith D, Suckling J, Taylor EM, Bullmore ET, Lingford-Hughes AR, Deakin B, Nutt DJ, Sahakian BJ, Robbins TW, Voon V; ICCAM Consortium. Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals. Addict Biol 2018;23:425-36. [PMID: 28247526 DOI: 10.1111/adb.12503] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
184 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
185 Bühler M, Mann K. Alcohol and the human brain: a systematic review of different neuroimaging methods. Alcohol Clin Exp Res. 2011;35:1771-1793. [PMID: 21777260 DOI: 10.1111/j.1530-0277.2011.01540.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 180] [Article Influence: 18.1] [Reference Citation Analysis]
186 Saitz R, Cheng DM, Winter M, Kim TW, Meli SM, Allensworth-Davies D, Lloyd-Travaglini CA, Samet JH. Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial. JAMA 2013;310:1156-67. [PMID: 24045740 DOI: 10.1001/jama.2013.277609] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
187 Diehl A, Ulmer L, Mutschler J, Herre H, Krumm B, Croissant B, Mann K, Kiefer F. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol Alcohol 2010;45:271-7. [PMID: 20348436 DOI: 10.1093/alcalc/agq017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
188 Finlay AK, Binswanger I, Timko C, Rosenthal J, Clark S, Blue-Howells J, McGuire J, Hagedorn H, Wong J, Van Campen J, Harris AHS. Receipt of Pharmacotherapy for Alcohol Use Disorder by Male Justice-Involved U.S. Veterans Health Administration Patients. Crim Justice Policy Rev 2018;29:875-90. [PMID: 30393426 DOI: 10.1177/0887403416644011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
189 Del Re AC, Maisel N, Blodgett JC, Wilbourne P, Finney JW. Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time. J Clin Psychopharmacol 2013;33:649-57. [PMID: 23857312 DOI: 10.1097/JCP.0b013e3182983e73] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
190 Blednov YA, Benavidez JM, Black M, Harris RA. Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci 2014;8:129. [PMID: 24904269 DOI: 10.3389/fnins.2014.00129] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
191 Soyka M, Rösner S. Emerging drugs to treat alcoholism. Expert Opin Emerg Drugs 2010;15:695-711. [PMID: 20560783 DOI: 10.1517/14728214.2010.500811] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
192 Wessell R, Edwards C. Biological and psychological interventions: trends in substance use disorders intervention research. Addict Behav 2010;35:1083-8. [PMID: 20729001 DOI: 10.1016/j.addbeh.2010.07.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
193 Addolorato G, Mirijello A, Leggio L, Ferrulli A, Landolfi R. Management of alcohol dependence in patients with liver disease. CNS Drugs. 2013;27:287-299. [PMID: 23456576 DOI: 10.1007/s40263-013-0043-4] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 6.2] [Reference Citation Analysis]
194 Asana OO, Ayvaci ER, Pollio DE, Hong BA, North CS. Associations of alcohol use disorder, alcohol use, housing, and service use in a homeless sample of 255 individuals followed over 2 years. Subst Abus 2018;39:497-504. [PMID: 29595364 DOI: 10.1080/08897077.2018.1449169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
195 Navarro M. The Role of the Melanocortin System in Drug and Alcohol Abuse. The Role of Neuropeptides in Addiction and Disorders of Excessive Consumption. Elsevier; 2017. pp. 121-50. [DOI: 10.1016/bs.irn.2017.06.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
196 Morley KC, Logge W, Pearson S, Baillie A, Haber PS. National trends in alcohol pharmacotherapy: Findings from an Australian claims database. Drug and Alcohol Dependence 2016;166:254-7. [DOI: 10.1016/j.drugalcdep.2016.06.027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
197 Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol 2008;6:125-50. [PMID: 19305793 DOI: 10.2174/157015908784533842] [Cited by in Crossref: 90] [Cited by in F6Publishing: 78] [Article Influence: 7.5] [Reference Citation Analysis]
198 Yoon G, Kim SW, Petrakis IL, Westermeyer J. High-Dose Naltrexone Treatment and Gender in Alcohol Dependence. Clin Neuropharmacol 2016;39:165-8. [PMID: 27046656 DOI: 10.1097/WNF.0000000000000152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Woo J, Rim HD. Acamprosate-induced Extrapyramidal Symptoms in an Elderly Patient with Alcohol Dependence. Clin Psychopharmacol Neurosci 2014;12:166-8. [PMID: 25191510 DOI: 10.9758/cpn.2014.12.2.166] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
200 Oslin DW, Lynch KG, Maisto SA, Lantinga LJ, McKay JR, Possemato K, Ingram E, Wierzbicki M. A randomized clinical trial of alcohol care management delivered in Department of Veterans Affairs primary care clinics versus specialty addiction treatment. J Gen Intern Med 2014;29:162-8. [PMID: 24052453 DOI: 10.1007/s11606-013-2625-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 8.0] [Reference Citation Analysis]
201 Boden MT, Hoggatt KJ. Substance Use Disorders Among Veterans in a Nationally Representative Sample: Prevalence and Associated Functioning and Treatment Utilization. J Stud Alcohol Drugs 2018;79:853-61. [PMID: 30573015 [PMID: 30573015 DOI: 10.15288/jsad.2018.79.853] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 5.3] [Reference Citation Analysis]
202 Zhu H, Luo S, DeSantis SM. Zero-inflated count models for longitudinal measurements with heterogeneous random effects. Stat Methods Med Res 2017;26:1774-86. [PMID: 26113383 DOI: 10.1177/0962280215588224] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
203 Berrettini W. Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. Prog Brain Res 2016;223:253-67. [PMID: 26806780 DOI: 10.1016/bs.pbr.2015.07.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
204 Doran CM, Duszynski KM, Beilby JJ, Mattick RP. Use of pharmacotherapies for the management of addictive behaviours in Australian clinical practice. Addictive Behaviors 2006;31:1947-58. [DOI: 10.1016/j.addbeh.2006.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
205 Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med 2008;359:715-21. [PMID: 18703474 DOI: 10.1056/NEJMct0801733] [Cited by in Crossref: 92] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
206 Kaminski BJ, Duke AN, Weerts EM. Effects of naltrexone on alcohol drinking patterns and extinction of alcohol seeking in baboons. Psychopharmacology (Berl) 2012;223:55-66. [PMID: 22451093 DOI: 10.1007/s00213-012-2688-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
207 Edenberg HJ, Kranzler HR. The contribution of genetics to addiction therapy approaches. Pharmacology & Therapeutics 2005;108:86-93. [DOI: 10.1016/j.pharmthera.2005.06.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
208 Worrell SD, Gould TJ. Therapeutic potential of ketamine for alcohol use disorder. Neurosci Biobehav Rev 2021;126:573-89. [PMID: 33989669 DOI: 10.1016/j.neubiorev.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Thorsell A. The μ-opioid receptor and treatment response to naltrexone. Alcohol Alcohol. 2013;48:402-408. [PMID: 23543091 DOI: 10.1093/alcalc/agt030] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
210 Mitchell JM, Grossman LE, Coker AR, Messing RO. The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. J Clin Psychopharmacol 2012;32:269-72. [PMID: 22367657 DOI: 10.1097/JCP.0b013e318248ba69] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
211 Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H. Opioid modulators for alcohol dependence. Expert Opinion on Investigational Drugs 2011;20:1073-86. [DOI: 10.1517/13543784.2011.592139] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
212 Rolland B, Bordet R, Cottencin O. Le baclofène devra aussi être comparé aux traitements validés de l’alcoolodépendance. La Presse Médicale 2012;41:107-8. [DOI: 10.1016/j.lpm.2011.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
213 Richardson K, Baillie A, Reid S, Morley K, Teesson M, Sannibale C, Weltman M, Haber P. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? Addiction 2008;103:953-9. [PMID: 18482418 DOI: 10.1111/j.1360-0443.2008.02215.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
214 Perney P, Rigole H, Blanc F. Alcoolodépendance : diagnostic et traitement. La Revue de Médecine Interne 2008;29:297-304. [DOI: 10.1016/j.revmed.2007.09.026] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
215 Rosenthal RN. Current and Future Drug Therapies for Alcohol Dependence. Journal of Clinical Psychopharmacology 2006;26:S20-9. [DOI: 10.1097/01.jcp.000246223.94119.cd] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
216 Henderson-Redmond A, Czachowski C. Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats. Psychopharmacology (Berl) 2014;231:4309-21. [PMID: 24770627 DOI: 10.1007/s00213-014-3571-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
217 Herbeck DM, Jeter KE, Cousins SJ, Abdelmaksoud R, Crèvecoeur-macphail D. Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone. Journal of Addictive Diseases 2016;35:305-14. [DOI: 10.1080/10550887.2016.1189659] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
218 Karpyak VM, Biernacka JM, Geske JR, Jenkins GD, Cunningham JM, Rüegg J, Kononenko O, Leontovich AA, Abulseoud OA, Hall-Flavin DK, Loukianova LL, Schneekloth TD, Skime MK, Frank J, Nöthen MM, Rietschel M, Kiefer F, Mann KF, Weinshilboum RM, Frye MA, Choi DS. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry 2014;4:e462. [PMID: 25290263 DOI: 10.1038/tp.2014.103] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
219 Collins SE, Duncan MH, Smart BF, Saxon AJ, Malone DK, Jackson TR, Ries RK. Extended-Release Naltrexone and Harm Reduction Counseling for Chronically Homeless People With Alcohol Dependence. Substance Abuse 2015;36:21-33. [DOI: 10.1080/08897077.2014.904838] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
220 De Sousa A. The pharmacotherapy of alcohol dependence: a state of the art review. Mens Sana Monogr 2010;8:69-82. [PMID: 21327171 DOI: 10.4103/0973-1229.58820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
221 Capurso NA. Naltrexone for the treatment of comorbid tobacco and pornography addiction: Naltrexone for Tobacco and Pornography Addiction. Am J Addict 2017;26:115-7. [DOI: 10.1111/ajad.12501] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
222 Perney P, Lehert P, Mason BJ. Sleep Disturbance in Alcoholism: Proposal of a Simple Measurement, and Results from a 24-Week Randomized Controlled Study of Alcohol-Dependent Patients Assessing Acamprosate Efficacy. Alcohol and Alcoholism 2012;47:133-9. [DOI: 10.1093/alcalc/agr160] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
223 Bilbeny N, Contreras S, Font M, Paeile C, García H. Effect of natural and synthetic polyamines on ethanol intake in UChB drinker rats. Alcohol 2005;36:169-77. [DOI: 10.1016/j.alcohol.2005.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
224 Krampe H, Spies CD, Ehrenreich H. Supervised Disulfiram in the Treatment of Alcohol Use Disorder: A Commentary: COMMENTARY. Alcoholism: Clinical and Experimental Research 2011;35:1732-6. [DOI: 10.1111/j.1530-0277.2011.01519.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
225 Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep 2011;13:374-81. [PMID: 21773951 DOI: 10.1007/s11920-011-0222-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 9.0] [Reference Citation Analysis]
226 Ghirmai S, Azar MR, Cashman JR. Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation. Bioorg Med Chem 2009;17:6671-81. [PMID: 19683449 DOI: 10.1016/j.bmc.2009.07.069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
227 Norman SB, Myers US, Wilkins KC, Goldsmith AA, Hristova V, Huang Z, McCullough KC, Robinson SK. Review of biological mechanisms and pharmacological treatments of comorbid PTSD and substance use disorder. Neuropharmacology 2012;62:542-51. [PMID: 21600225 DOI: 10.1016/j.neuropharm.2011.04.032] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
228 Hulse GK. Improving clinical outcomes for naltrexone as a management of problem alcohol use. Br J Clin Pharmacol 2013;76:632-41. [PMID: 22946873 DOI: 10.1111/j.1365-2125.2012.04452.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
229 Abraham AJ, Knudsen HK, Roman PM. A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation. J Stud Alcohol Drugs 2011;72:669-77. [PMID: 21683049 DOI: 10.15288/jsad.2011.72.669] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
230 Ooteman W, Verheul R, Naassila M, Daoust M, Schippers GM, Koeter MWJ, van den Brink W. Patient‐treatment matching with anti‐craving medications in alcohol‐dependent patients: A review on phenotypic, endophenotypic and genetic indicators. Journal of Substance Use 2009;10:75-96. [DOI: 10.1080/14659890500038764] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
231 van der Zwaluw CS, van den Wildenberg E, Wiers RW, Franke B, Buitelaar J, Scholte RH, Engels RC. Polymorphisms in the µ-opioid receptor gene ( OPRM1 ) and the implications for alcohol dependence in humans. Pharmacogenomics 2007;8:1427-36. [DOI: 10.2217/14622416.8.10.1427] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
232 Starski P, Hong SI, Peyton L, Oliveros A, Wininger K, Hutchison C, Kang S, Karpyak V, Choi DS. Ethanol induces maladaptive impulse control and decreased seeking behaviors in mice. Addict Biol 2020;25:e12754. [PMID: 31012186 DOI: 10.1111/adb.12754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
233 Abraham AJ, Andrews CM, Harris SJ, Friedmann PD. Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. Neurotherapeutics 2020;17:55-69. [PMID: 31907876 DOI: 10.1007/s13311-019-00814-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
234 DeSantis SM, Zhu H. A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials. Med Decis Making 2014;34:899-910. [PMID: 24935915 DOI: 10.1177/0272989X14537558] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
235 Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug Alcohol Depend 2017;174:158-70. [PMID: 28334661 DOI: 10.1016/j.drugalcdep.2017.01.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
236 Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108:275-293. [PMID: 23075288 DOI: 10.1111/j.1360-0443.2012.04054.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 176] [Article Influence: 19.9] [Reference Citation Analysis]
237 Sprow GM, Thiele TE. The neurobiology of binge-like ethanol drinking: evidence from rodent models. Physiol Behav 2012;106:325-31. [PMID: 22245775 DOI: 10.1016/j.physbeh.2011.12.026] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 6.1] [Reference Citation Analysis]
238 Ciccocioppo R, Economidou D, Rimondini R, Sommer W, Massi M, Heilig M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry 2007;61:4-12. [PMID: 16533497 DOI: 10.1016/j.biopsych.2006.01.006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.0] [Reference Citation Analysis]
239 Richard JM, Fields HL. Mu-opioid receptor activation in the medial shell of nucleus accumbens promotes alcohol consumption, self-administration and cue-induced reinstatement. Neuropharmacology 2016;108:14-23. [PMID: 27089981 DOI: 10.1016/j.neuropharm.2016.04.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
240 Boschloo L, Vogelzangs N, Smit JH, van den Brink W, Veltman DJ, Beekman AT, Penninx BW. The performance of the Alcohol Use Disorder Identification Test (AUDIT) in detecting alcohol abuse and dependence in a population of depressed or anxious persons. J Affect Disord 2010;126:441-6. [PMID: 20537398 DOI: 10.1016/j.jad.2010.04.019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
241 Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother. 2005;6:2103-2115. [PMID: 16197362 DOI: 10.1517/14656566.6.12.2103] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
242 Peng JL, Patel MP, McGee B, Liang T, Chandler K, Tayarachakul S, O'Connor S, Liangpunsakul S. Management of alcohol misuse in patients with liver diseases. J Investig Med 2017;65:673-80. [PMID: 27940551 DOI: 10.1136/jim-2016-000254] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
243 Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;CD004332. [PMID: 20824837 DOI: 10.1002/14651858.cd004332.pub2] [Cited by in Crossref: 70] [Cited by in F6Publishing: 92] [Article Influence: 5.8] [Reference Citation Analysis]
244 Thomas SE, Miller PM, Randall PK, Book SW. Improving acceptance of naltrexone in community addiction treatment centers: a pilot study. J Subst Abuse Treat 2008;35:260-8. [PMID: 18329227 DOI: 10.1016/j.jsat.2007.11.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
245 Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, Klassen P, Fujioka K; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36:4022-9. [PMID: 24144653 DOI: 10.2337/dc13-0234] [Cited by in Crossref: 209] [Cited by in F6Publishing: 181] [Article Influence: 23.2] [Reference Citation Analysis]
246 Mitchell JM, O'Neil JP, Janabi M, Marks SM, Jagust WJ, Fields HL. Alcohol consumption induces endogenous opioid release in the human orbitofrontal cortex and nucleus accumbens. Sci Transl Med 2012;4:116ra6. [PMID: 22238334 DOI: 10.1126/scitranslmed.3002902] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 12.3] [Reference Citation Analysis]
247 Mannelli P, Peindl K, Masand PS, Patkar AA. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother 2007;7:1265-77. [PMID: 17939765 DOI: 10.1586/14737175.7.10.1265] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
248 Kranzler HR, Koob G, Gastfriend DR, Swift RM, Willenbring ML. Advances in the Pharmacotherapy of Alcoholism: Challenging Misconceptions. Alcoholism Clin Exp Res 2006;30:272-81. [DOI: 10.1111/j.1530-0277.2006.00022.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
249 Dermody SS, Wardell JD, Stoner SA, Hendershot CS. Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention. Ann Behav Med 2018;52:787-97. [PMID: 30124761 DOI: 10.1093/abm/kax053] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
250 Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr Scand 2021;143:101-18. [PMID: 33125716 DOI: 10.1111/acps.13249] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
251 Escher T, Mittleman G. Schedule-induced alcohol drinking: non-selective effects of acamprosate and naltrexone. Addict Biol 2006;11:55-63. [PMID: 16759337 DOI: 10.1111/j.1369-1600.2006.00004.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
252 Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008;75:218-65. [PMID: 17706608 DOI: 10.1016/j.bcp.2007.06.039] [Cited by in Crossref: 312] [Cited by in F6Publishing: 315] [Article Influence: 20.8] [Reference Citation Analysis]
253 Vuoristo-Myllys S, Lipsanen J, Lahti J, Kalska H, Alho H. Outcome predictors for problem drinkers treated with combined cognitive behavioral therapy and naltrexone. Am J Drug Alcohol Abuse 2014;40:103-10. [PMID: 24456403 DOI: 10.3109/00952990.2013.853074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
254 Warnault V, Darcq E, Morisot N, Phamluong K, Wilbrecht L, Massa SM, Longo FM, Ron D. The BDNF Valine 68 to Methionine Polymorphism Increases Compulsive Alcohol Drinking in Mice That Is Reversed by Tropomyosin Receptor Kinase B Activation. Biol Psychiatry 2016;79:463-73. [PMID: 26204799 DOI: 10.1016/j.biopsych.2015.06.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
255 Carnicella S, Ahmadiantehrani S, He DY, Nielsen CK, Bartlett SE, Janak PH, Ron D. Cabergoline decreases alcohol drinking and seeking behaviors via glial cell line-derived neurotrophic factor. Biol Psychiatry 2009;66:146-53. [PMID: 19232578 DOI: 10.1016/j.biopsych.2008.12.022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
256 Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial: Baclofen for AUD in veterans with HCV. Addiction 2017;112:1173-83. [DOI: 10.1111/add.13787] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
257 Hagedorn HJ, Wisdom JP, Gerould H, Pinsker E, Brown R, Dawes M, Dieperink E, Myrick DH, Oliva EM, Wagner TH, Harris AHS. Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. Addict Sci Clin Pract 2019;14:24. [PMID: 31291996 DOI: 10.1186/s13722-019-0151-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
258 Liang J, Olsen RW. Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. Acta Pharmacol Sin 2014;35:981-93. [PMID: 25066321 DOI: 10.1038/aps.2014.50] [Cited by in Crossref: 61] [Cited by in F6Publishing: 50] [Article Influence: 8.7] [Reference Citation Analysis]
259 Anton RF. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics 2008;9:655-8. [DOI: 10.2217/14622416.9.6.655] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
260 Canidate SS, Carnaby GD, Cook CL, Cook RL. A Systematic Review of Naltrexone for Attenuating Alcohol Consumption in Women with Alcohol Use Disorders. Alcohol Clin Exp Res 2017;41:466-72. [PMID: 28247556 DOI: 10.1111/acer.13313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
261 d'Abbs P, Togni S, Rosewarne C, Boffa J. The Grog Mob: lessons from an evaluation of a multi-disciplinary alcohol intervention for Aboriginal clients. Australian and New Zealand Journal of Public Health 2013;37:450-6. [DOI: 10.1111/1753-6405.12122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
262 Björk K, Hansson AC, Sommer WH. Genetic Variation and Brain Gene Expression in Rodent Models of Alcoholism. Functional Plasticity and Genetic Variation: Insights into the Neurobiology of Alcoholism. Elsevier; 2010. pp. 129-71. [DOI: 10.1016/s0074-7742(10)91005-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
263 Patriquin MA, Bauer IE, Soares JC, Graham DP, Nielsen DA. Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet 2015;25:181-93. [PMID: 26146874 DOI: 10.1097/YPG.0000000000000095] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
264 Iversen L, Morris K, Nutt D. Pharmacology and Treatments. Drugs and the Future. Elsevier; 2007. pp. 169-208. [DOI: 10.1016/b978-012370624-9/50009-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Garbutt JC, Greenblatt AM, West SL, Morgan LC, Kampov-Polevoy A, Jordan HS, Bobashev GV. Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. Addiction 2014;109:1274-84. [PMID: 24661324 DOI: 10.1111/add.12557] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]